AMERICAN PHARMA GIANT Bristol Myers Squibb has just UNLEASHED a TERRIFYING new reality by signing a multi-BILLION dollar pact to SHIP American-developed experimental drugs to COMMUNIST CHINA for testing. This is not a simple licensing deal—it’s a full-scale SURRENDER of U.S. medical sovereignty, handing over our most promising treatments to a geopolitical rival with a dismal human rights record.
Industry insiders are calling this a “HUGE SIGNAL,” but what it truly signals is the END of American dominance in biopharma. In a shocking betrayal, Big Pharma is now actively building China INTO its core research and development system. This isn’t outsourcing—it’s an UNPRECEDENTED transfer of intellectual property and patient data to a nation where ethical standards are NOTORIOUSLY opaque.
The chilling truth? Over HALF of all major pharma licensing deals now originate in China, a STAGGERING leap from just 5% two years ago. The playbook has been flipped: instead of merely buying Chinese discoveries, U.S. giants like Pfizer, Merck, and AstraZeneca are now funneling their OWN groundbreaking research to China because trials are FASTER and DIRT CHEAP. One venture capitalist brazenly admits that conducting early-stage drug discovery in the U.S. will soon be as unrealistic as “making the iPhone in the U.S.”
This is a FIRE SALE of American medical innovation, sacrificing long-term security and quality control for short-term profit, with YOUR health on the line. The very companies entrusted with our well-being are constructing a global supply chain for medicine where the CCP holds critical leverage. The future of your prescriptions is being written in a lab in Lianyungang, not in New Jersey. Ask yourself: who really controls the cure?
Author: Kayitsi.com
